Media Coverage
"Inner Workings: Zebrafish assay forges new approach to drug discovery" Proc. Natl. Acad. Sci. May 22, 2018
"From Screen to Trial: Evidence-Based Decisions for Drug-Induced Hearing Loss", The Hearing Journal, April 2018 Vol 71(4): 8-9.
"Potential Therapy for CF Patients with Hearing Loss Due to Antibiotics OK’d for Clinical Trial" Cystic Fibrosis News Today, February 8, 2018
"FDA OK's UW-created therapy to protect hearing" UW News, February 5, 2018
"Preventing Chemo-induced Hearing Loss" Hutch News, June 7, 2017
"These Drugs Can Hurt Your Hearing" AARP Blogs Katherine Bouton, February 12, 2016.
"Sound Science: Emerging Technology and a Wide-open Market are Spurring More Companies to Pursue Drugs to Treat or Prevent Hearing Loss," Chemical and Engineering News, April 7, 2014, including an interview with Edwin W Rubel.
Life Sciences Discovery Fund Grant awarded for mammalian efficacy testing
Oricula Therapeutics, LLC, raises initial funding
"Can a Tiny Fish Save Your Ears?", Wall Street Journal, August 5, 2009. Article related to the early research into the use of zebrafish for screening potential compounds
Press Releases
Sept 27, 2018. Decibel Therapeutics and Oricula Therapeutics Announce Exclusive License for ORC-13661 Development for Hearing and Balance Protection.
August 30, 2018. Oricula Therapeutics Advances Hearing Loss Treatment Candidate ORC-13661 to Phase 1 Multiple Ascending Dose Trial
February 5, 2018. FDA Clears Oricula Therapeutics Investigational New Drug Application for Clinical Trials
February 1, 2016. Oricula Therapeutics Secures $2M National Institutes of Health Grant to Further Develop Medicine to Preserve Hearing
April 30, 2014: Oricula Therapeutics Secures National Institutes of Health Grant to Further Develop Medicine to Preserve Hearing
April 9, 2014: Oricula Therapeutics Secures Intellectual Property and Takes First Step to Commercialize Medicine to Preserve Hearing
Published Research
Oricula founders and collaborators report on development of our clinical lead ORC-13661 in the JCI Insight, entitled Fluorescent aminoglycosides reveal intracellular trafficking routes in mechanosensory hair cells.
Oricula CEO publishes study of hearing loss in cystic fibrosis patients along with Erika Zettner from UCSD, entitled Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients.
Oricula CEO publishes study of hearing loss in cystic fibrosis patients along with Erika Zettner from UCSD, entitled Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment.
Oricula founders and collaborators report on development of our clinical lead ORC-13661 in the Journal of Medicinal Chemistry. The report was highlighted in the journal and recommended for the Pharmacology and Drug Discovery section of Faculty of 1000.
Visit Our Team for additional links to published articles by our individual researchers.